LLY
Eli Lilly and Company
Price Chart
Latest Quote
$1134.60
+9.33 (+0.83%)
Current Price
| Previous Close | $1125.27 |
| Open | $1142.97 |
| Day High | $1166.29 |
| Day Low | $1132.34 |
| Volume | 3,195,740 |
Stock Information
| Quarterly Dividend / Yield | $6.92 / 0.61% |
| Shares Outstanding | 891.74M |
| Quarterly Dividend Yield | 0.61% |
| Quarterly Dividend | $6.92 |
| Total Debt | $43.37B |
| Cash Equivalents | $5.28B |
| Revenue | $72.25B |
| Net Income | $25.28B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $1.01T |
| P/E Ratio | 40.22 |
| EPS (TTM) | $28.13 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.04T |
| Sales | $72.25B |
| Income | $25.28B |
| Book/sh | $34.92 |
| Cash/sh | $5.92 |
| Employees | 50K |
Financial Ratios
| Quick Ratio | 0.72 |
| Current Ratio | 1.50 |
| Debt/Eq | 139.01 |
| EPS Growth TTM | 168.10% |
Returns & Margins
| ROA | 20.74% |
| ROE | 107.46% |
| Gross Margin | 82.83% |
| Operating Margin | 49.39% |
| Profit Margin | 34.99% |
Ownership
| Insider Ownership | 0.16% |
| Institutional Ownership | 85.33% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 25.43 |
| PEG | 1.45 |
| P/S | 13.96 |
| P/B | 32.40 |
Analyst Data
| Recommendation | buy |
| Target Price | $1215.10 |
Technical Indicators
| SMA20 | $1046.03 |
| SMA50 | $971.90 |
| SMA200 | $944.83 |
| RSI | 71.73 |
| ATR | 37.2414 |
| Shares Float | 889.33M |
| Short Float | 0.95% |
| Short Ratio | 2.44 |
| Volatility | 0.52 |
| Rel Volume | 1.28 |
Performance History
| Week | +2.39% |
| Month | +14.82% |
| Quarter | +14.44% |
| 6 Months | +9.84% |
| YTD | +5.08% |
| Year | +48.78% |
| 3 Years | +169.13% |
| 5 Years | +493.81% |
| 10 Years | +1676.64% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $1131.42 | 4,079,082 |
| 2026-06-04 | $1125.27 | 4,046,700 |
| 2026-06-03 | $1078.78 | 2,655,600 |
| 2026-06-02 | $1064.15 | 2,408,500 |
| 2026-06-01 | $1082.20 | 2,693,400 |
| 2026-05-29 | $1105.00 | 4,600,800 |
| 2026-05-28 | $1126.80 | 4,600,700 |
| 2026-05-27 | $1082.92 | 2,583,000 |
| 2026-05-26 | $1064.74 | 2,981,000 |
| 2026-05-22 | $1065.00 | 3,470,600 |
| 2026-05-21 | $1041.65 | 2,705,200 |
| 2026-05-20 | $1018.87 | 2,998,800 |
| 2026-05-19 | $1021.41 | 3,796,000 |
| 2026-05-18 | $988.09 | 2,016,000 |
| 2026-05-15 | $1004.92 | 2,820,700 |
| 2026-05-14 | $1004.97 | 1,751,700 |
| 2026-05-13 | $1014.00 | 3,486,400 |
| 2026-05-12 | $988.17 | 3,037,500 |
| 2026-05-11 | $965.33 | 3,517,500 |
| 2026-05-08 | $946.82 | 3,559,200 |
| 2026-05-07 | $973.28 | 3,494,900 |
| 2026-05-06 | $985.35 | 3,921,200 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
đ° Latest News
Dow Jones Futures Rise, Techs Fall As AI Trade Cools; Jobs Report Looms
Investor's Business Daily âĸ 2026-06-05T21:15:02Z
Dow Jones Futures: What To Do As Market Rally Faces First Real Test; SpaceX IPO, Apple, Oracle Loom
Investor's Business Daily âĸ 2026-06-05T21:07:03Z
UnitedHealth, Eli Lilly Lead Healthcare Rebound as Investors Seek Stability
GuruFocus.com âĸ 2026-06-05T18:32:18ZNovo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally
GuruFocus.com âĸ 2026-06-05T18:31:08ZGLP-1 Sales Forecast Jumps To $150 Billion By 2030
GuruFocus.com âĸ 2026-06-05T17:19:33ZHereâs Why Eli Lilly (LLY) is Among the 10 Best American Stocks to Buy and Hold for the Next Decade
Insider Monkey âĸ 2026-06-05T16:46:39Z
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
Zacks âĸ 2026-06-05T15:47:00Z
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
Insider Monkey âĸ 2026-06-05T14:14:23Z
Jim Cramer Details How Eli Lilly Could Defeat Competitors
Insider Monkey âĸ 2026-06-05T14:14:21Z
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
Zacks âĸ 2026-06-05T13:34:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $11,052,000,000 | $8,418,000,000 | $7,082,000,000 | $6,629,800,000 |
| Cost Of Revenue | $11,052,000,000 | $8,418,000,000 | $7,082,000,000 | $6,629,800,000 |
| Total Revenue | $65,179,000,000 | $45,043,000,000 | $34,124,000,000 | $28,541,400,000 |
| Operating Revenue | $65,179,000,000 | $45,043,000,000 | $34,124,000,000 | $28,541,400,000 |
| Expenses | ||||
| Total Expenses | $35,483,000,000 | $28,003,000,000 | $23,799,000,000 | $20,261,000,000 |
| Other Income Expense | $-3,965,000,000 | $-4,360,000,000 | $-3,771,000,000 | $-1,205,200,000 |
| Other Non Operating Income Expenses | $-571,000,000 | $-219,000,000 | $97,000,000 | $358,600,000 |
| Operating Expense | $24,431,000,000 | $19,585,000,000 | $16,717,000,000 | $13,631,200,000 |
| Interest Expense | - | $780,600,000 | $485,900,000 | $331,600,000 |
| Net Non Operating Interest Income Expense | - | $-605,400,000 | $-312,300,000 | $-268,800,000 |
| Interest Expense Non Operating | - | $780,600,000 | $485,900,000 | $331,600,000 |
| General And Administrative Expense | - | $8,593,800,000 | $7,403,100,000 | $6,440,400,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $20,640,000,000 | $10,590,000,000 | $5,240,000,000 | $6,244,800,000 |
| Normalized Income | $23,362,481,054 | $14,048,453,470 | $8,330,532,000 | $7,678,804,600 |
| Net Income From Continuing And Discontinued Operation | $20,640,000,000 | $10,590,000,000 | $5,240,000,000 | $6,244,800,000 |
| Net Income Common Stockholders | $20,640,000,000 | $10,590,000,000 | $5,240,000,000 | $6,244,800,000 |
| Net Income | $20,640,000,000 | $10,590,000,000 | $5,240,000,000 | $6,244,800,000 |
| Net Income Including Noncontrolling Interests | $20,640,000,000 | $10,590,000,000 | $5,240,000,000 | $6,244,800,000 |
| Net Income Continuous Operations | $20,640,000,000 | $10,590,000,000 | $5,240,000,000 | $6,244,800,000 |
| Pretax Income | $25,731,000,000 | $12,680,000,000 | $6,554,000,000 | $6,806,400,000 |
| Special Income Charges | $-3,394,000,000 | $-4,141,000,000 | $-3,868,000,000 | $-1,153,100,000 |
| Operating Income | $29,696,000,000 | $17,040,000,000 | $10,325,000,000 | $8,280,400,000 |
| Gross Profit | $54,127,000,000 | $36,625,000,000 | $27,042,000,000 | $21,911,600,000 |
| Net Interest Income | - | $-605,400,000 | $-312,300,000 | $-268,800,000 |
| Interest Income | - | $175,200,000 | $173,600,000 | $62,800,000 |
| Interest Income Non Operating | - | $175,200,000 | $173,600,000 | $62,800,000 |
| Net Income Discontinuous Operations | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $22.95 | $11.71 | $5.80 | $6.57 |
| Basic EPS | $23.07 | $11.80 | $5.83 | $6.57 |
| Other | ||||
| Tax Effect Of Unusual Items | $-671,518,946 | $-682,546,530 | $-777,468,000 | $-129,795,400 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $35,087,000,000 | $22,948,000,000 | $15,720,000,000 | $10,224,300,000 |
| Total Unusual Items | $-3,394,000,000 | $-4,141,000,000 | $-3,868,000,000 | $-1,563,800,000 |
| Total Unusual Items Excluding Goodwill | $-3,394,000,000 | $-4,141,000,000 | $-3,868,000,000 | $-1,563,800,000 |
| Reconciled Depreciation | $1,997,000,000 | $1,767,000,000 | $1,527,000,000 | $1,522,500,000 |
| EBITDA (Bullshit earnings) | $31,693,000,000 | $18,807,000,000 | $11,852,000,000 | $8,660,500,000 |
| EBIT | $29,696,000,000 | $17,040,000,000 | $10,325,000,000 | $7,138,000,000 |
| Diluted Average Shares | $899,301,000 | $904,059,000 | $903,284,000 | $950,182,000 |
| Basic Average Shares | $894,800,000 | $897,538,000 | $899,379,000 | $950,182,000 |
| Diluted NI Availto Com Stockholders | $20,640,000,000 | $10,590,000,000 | $5,240,000,000 | $6,244,800,000 |
| Tax Provision | $5,091,000,000 | $2,090,000,000 | $1,314,000,000 | $561,600,000 |
| Other Special Charges | $2,910,000,000 | $3,280,000,000 | $3,800,000,000 | $908,500,000 |
| Write Off | $484,000,000 | $861,000,000 | $68,000,000 | $244,600,000 |
| Restructuring And Mergern Acquisition | $2,910,000,000 | $3,280,000,000 | $45,500,000 | $23,000,000 |
| Research And Development | $13,337,000,000 | $10,991,000,000 | $9,313,000,000 | $7,190,800,000 |
| Selling General And Administration | $11,094,000,000 | $8,594,000,000 | $7,404,000,000 | $6,440,400,000 |
| Gain On Sale Of Security | - | $-49,500,000 | $-20,200,000 | $-410,700,000 |
| Other Gand A | - | $8,593,800,000 | $7,403,100,000 | $6,440,400,000 |
| Salaries And Wages | - | $-461,700,000 | $-461,900,000 | $-372,900,000 |
| Gain On Sale Of Business | - | - | - | - |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-06-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $14,115,000,000 | $2,336,000,000 | $-1,074,400,000 | $-629,800,000 |
| Total Assets | $112,476,000,000 | $78,715,000,000 | $64,006,300,000 | $49,489,800,000 |
| Total Non Current Assets | $56,847,000,000 | $45,976,000,000 | $38,279,300,000 | $31,455,300,000 |
| Other Non Current Assets | $6,992,000,000 | $5,720,000,000 | $4,989,900,000 | $4,337,000,000 |
| Non Current Deferred Assets | $9,959,000,000 | $8,001,000,000 | $5,477,300,000 | $2,792,900,000 |
| Non Current Deferred Taxes Assets | $9,959,000,000 | $8,001,000,000 | $5,477,300,000 | $2,792,900,000 |
| Investmentin Financial Assets | $668,000,000 | $1,209,000,000 | $1,481,900,000 | $1,642,300,000 |
| Goodwill And Other Intangible Assets | $12,420,000,000 | $11,936,000,000 | $11,846,300,000 | $11,279,600,000 |
| Other Intangible Assets | $6,522,000,000 | $6,166,000,000 | $6,906,600,000 | $7,206,600,000 |
| Current Assets | $55,629,000,000 | $32,740,000,000 | $25,727,000,000 | $18,034,500,000 |
| Other Current Assets | $147,000,000 | $266,000,000 | $149,500,000 | $7,300,000 |
| Prepaid Assets | $14,315,000,000 | $8,341,000,000 | $5,540,800,000 | $2,946,800,000 |
| Inventory | $13,744,000,000 | $7,589,000,000 | $5,772,800,000 | $4,309,700,000 |
| Receivables | $20,155,000,000 | $13,276,000,000 | $11,336,200,000 | $8,558,900,000 |
| Other Receivables | $2,395,000,000 | $2,270,000,000 | $2,245,700,000 | $1,662,900,000 |
| Accounts Receivable | $17,760,000,000 | $11,006,000,000 | $9,090,500,000 | $6,896,000,000 |
| Cash Cash Equivalents And Short Term Investments | $7,268,000,000 | $3,268,000,000 | $2,927,700,000 | $2,211,800,000 |
| Cash And Cash Equivalents | $7,268,000,000 | $3,268,000,000 | $2,818,600,000 | $2,067,000,000 |
| Allowance For Doubtful Accounts Receivable | - | $-14,900,000 | $-14,800,000 | $-16,000,000 |
| Gross Accounts Receivable | - | $11,020,600,000 | $9,105,300,000 | $6,912,000,000 |
| Cash Equivalents | - | - | $1,088,400,000 | $657,400,000 |
| Cash Financial | - | - | $1,730,200,000 | $1,409,600,000 |
| Debt | ||||
| Net Debt | $35,235,000,000 | $30,376,000,000 | $22,406,700,000 | $14,171,600,000 |
| Total Debt | $42,503,000,000 | $33,644,000,000 | $25,225,300,000 | $16,238,600,000 |
| Long Term Debt And Capital Lease Obligation | $40,868,000,000 | $28,527,000,000 | $18,320,800,000 | $14,737,500,000 |
| Long Term Debt | $40,868,000,000 | $28,527,000,000 | $18,320,800,000 | $14,737,500,000 |
| Current Debt And Capital Lease Obligation | $1,635,000,000 | $5,117,000,000 | $6,904,500,000 | $1,501,100,000 |
| Current Debt | $1,635,000,000 | $5,117,000,000 | $6,904,500,000 | $1,501,100,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $85,941,000,000 | $64,443,000,000 | $53,142,600,000 | $38,714,400,000 |
| Total Non Current Liabilities Net Minority Interest | $50,713,000,000 | $36,067,000,000 | $25,849,400,000 | $21,576,200,000 |
| Other Non Current Liabilities | $3,970,000,000 | $3,479,000,000 | $2,240,600,000 | $1,824,000,000 |
| Tradeand Other Payables Non Current | $5,875,000,000 | $4,061,000,000 | $3,849,200,000 | $3,709,600,000 |
| Current Liabilities | $35,228,000,000 | $28,376,000,000 | $27,293,200,000 | $17,138,200,000 |
| Other Current Liabilities | $8,457,000,000 | $6,397,000,000 | $3,281,300,000 | $2,845,400,000 |
| Payables And Accrued Expenses | $22,761,000,000 | $14,768,000,000 | $15,457,000,000 | $11,731,900,000 |
| Payables | $5,379,000,000 | $3,229,000,000 | $3,768,000,000 | $2,947,800,000 |
| Accounts Payable | $5,379,000,000 | $3,229,000,000 | $2,598,800,000 | $1,930,600,000 |
| Dividends Payable | - | $1,346,300,000 | $1,169,200,000 | $1,017,200,000 |
| Non Current Deferred Liabilities | - | - | - | $87,300,000 |
| Non Current Deferred Taxes Liabilities | - | - | - | $87,300,000 |
| Total Tax Payable | - | - | - | $475,100,000 |
| Income Tax Payable | - | - | - | $475,100,000 |
| Equity | ||||
| Common Stock Equity | $26,535,000,000 | $14,272,000,000 | $10,771,900,000 | $10,649,800,000 |
| Total Equity Gross Minority Interest | $26,535,000,000 | $14,272,000,000 | $10,863,700,000 | $10,775,400,000 |
| Stockholders Equity | $26,535,000,000 | $14,272,000,000 | $10,771,900,000 | $10,649,800,000 |
| Other Equity Interest | $-2,991,000,000 | $-2,982,000,000 | $-3,013,200,000 | $-3,013,200,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,880,000,000 | $-4,322,000,000 | $-4,327,000,000 | $-3,844,600,000 |
| Other Equity Adjustments | $-2,880,000,000 | $-4,322,000,000 | $-4,327,000,000 | $-3,844,600,000 |
| Retained Earnings | $24,470,000,000 | $13,545,000,000 | $10,312,300,000 | $10,042,600,000 |
| Long Term Equity Investment | $2,134,000,000 | $2,007,000,000 | $1,570,300,000 | $1,259,500,000 |
| Other | ||||
| Treasury Shares Number | $50,000,000 | $50,365,000 | $50,402,000 | $450,000 |
| Ordinary Shares Number | $894,800,000 | $897,538,000 | $899,379,000 | $950,182,000 |
| Share Issued | $944,800,000 | $947,903,000 | $949,781,000 | $950,632,000 |
| Tangible Book Value | $14,115,000,000 | $2,336,000,000 | $-1,074,400,000 | $-629,800,000 |
| Invested Capital | $69,038,000,000 | $47,916,000,000 | $35,997,200,000 | $26,888,400,000 |
| Working Capital | $20,401,000,000 | $4,364,000,000 | $-1,566,200,000 | $896,300,000 |
| Total Capitalization | $67,403,000,000 | $42,799,000,000 | $29,092,700,000 | $25,387,300,000 |
| Additional Paid In Capital | $7,346,000,000 | $7,439,000,000 | $7,250,400,000 | $6,921,400,000 |
| Capital Stock | $590,000,000 | $592,000,000 | $593,600,000 | $594,100,000 |
| Common Stock | $590,000,000 | $592,000,000 | $593,600,000 | $594,100,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,375,000,000 | $2,094,000,000 | $1,650,400,000 | $1,059,800,000 |
| Current Accrued Expenses | $17,382,000,000 | $11,539,000,000 | $11,689,000,000 | $8,784,100,000 |
| Investments And Advances | $2,802,000,000 | $3,216,000,000 | $3,052,200,000 | $2,901,800,000 |
| Available For Sale Securities | $668,000,000 | $1,209,000,000 | $1,267,600,000 | $1,428,400,000 |
| Goodwill | $5,898,000,000 | $5,770,000,000 | $4,939,700,000 | $4,073,000,000 |
| Net PPE | $24,674,000,000 | $17,103,000,000 | $12,913,600,000 | $10,144,000,000 |
| Accumulated Depreciation | $-12,560,000,000 | $-11,789,000,000 | $-11,099,300,000 | $-10,233,400,000 |
| Gross PPE | $37,234,000,000 | $28,892,000,000 | $24,012,900,000 | $20,377,400,000 |
| Construction In Progress | $13,013,000,000 | $8,245,000,000 | $5,084,100,000 | $2,798,600,000 |
| Other Properties | $13,486,000,000 | $11,458,000,000 | $10,329,000,000 | $9,406,300,000 |
| Buildings And Improvements | $10,088,000,000 | $8,807,000,000 | $8,280,000,000 | $7,915,900,000 |
| Land And Improvements | $647,000,000 | $382,000,000 | $319,800,000 | $256,600,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $43,000,000 | $63,000,000 | $102,400,000 | $8,900,000 |
| Finished Goods | $1,931,000,000 | $1,221,000,000 | $791,700,000 | $901,200,000 |
| Work In Process | $8,183,000,000 | $3,979,000,000 | $3,248,600,000 | $2,597,700,000 |
| Raw Materials | $3,587,000,000 | $2,326,000,000 | $1,630,100,000 | $801,900,000 |
| Minority Interest | - | $79,500,000 | $91,800,000 | $125,600,000 |
| Treasury Stock | - | $49,500,000 | $44,200,000 | $50,500,000 |
| Employee Benefits | - | $1,300,500,000 | $1,438,800,000 | $1,305,100,000 |
| Non Current Pension And Other Postretirement Benefit Plans | - | $1,300,500,000 | $1,438,800,000 | $1,305,100,000 |
| Held To Maturity Securities | - | $211,400,000 | $214,300,000 | $213,900,000 |
| Inventories Adjustments Allowances | - | $62,900,000 | $102,400,000 | $8,900,000 |
| Other Short Term Investments | - | $154,800,000 | $109,100,000 | $144,800,000 |
Fetched: 2026-06-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $5,964,000,000 | $414,000,000 | $-3,152,000,000 | $4,600,400,000 |
| Operating Activities | ||||
| Operating Cash Flow | $16,813,000,000 | $8,818,000,000 | $4,240,000,000 | $7,585,700,000 |
| Cash Flow From Continuing Operating Activities | $16,813,000,000 | $8,818,000,000 | $4,240,000,000 | $7,585,700,000 |
| Operating Gains Losses | $-180,000,000 | $-224,000,000 | $-1,879,000,000 | $263,500,000 |
| Investing Activities | ||||
| Capital Expenditure | $-10,849,000,000 | $-8,404,000,000 | $-7,392,000,000 | $-2,985,300,000 |
| Investing Cash Flow | $-10,972,000,000 | $-9,302,000,000 | $-7,153,000,000 | $-3,762,900,000 |
| Cash Flow From Continuing Investing Activities | $-10,972,000,000 | $-9,302,000,000 | $-7,153,000,000 | $-3,762,900,000 |
| Net Other Investing Changes | $1,000,000 | $-248,000,000 | $-98,000,000 | $-302,200,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-4,108,000,000 | $-2,500,000,000 | $-750,000,000 | $-1,500,000,000 |
| Financing Cash Flow | $-2,213,000,000 | $1,230,000,000 | $3,496,000,000 | $-5,406,700,000 |
| Cash Flow From Continuing Financing Activities | $-2,213,000,000 | $1,230,000,000 | $3,496,000,000 | $-5,406,700,000 |
| Net Other Financing Charges | $-772,000,000 | $-491,000,000 | $-335,000,000 | $-308,900,000 |
| Cash Dividends Paid | $-5,384,000,000 | $-4,680,000,000 | $-4,069,000,000 | $-3,535,800,000 |
| Common Stock Dividend Paid | $-5,384,000,000 | $-4,680,000,000 | $-4,069,000,000 | $-3,535,800,000 |
| Net Common Stock Issuance | $-4,108,000,000 | $-2,500,000,000 | $-750,000,000 | $-1,500,000,000 |
| Other | ||||
| Repayment Of Debt | $-778,000,000 | $-664,000,000 | $0 | $-1,560,000,000 |
| Issuance Of Debt | $13,167,000,000 | $11,417,000,000 | $3,959,000,000 | $0 |
| End Cash Position | $7,268,000,000 | $3,268,000,000 | $2,819,000,000 | $2,067,000,000 |
| Beginning Cash Position | $3,268,000,000 | $2,819,000,000 | $2,067,000,000 | $3,818,500,000 |
| Effect Of Exchange Rate Changes | $372,000,000 | $-297,000,000 | $169,000,000 | $-167,600,000 |
| Changes In Cash | $3,628,000,000 | $746,000,000 | $583,000,000 | $-1,583,900,000 |
| Common Stock Payments | $-4,108,000,000 | $-2,500,000,000 | $-750,000,000 | $-1,500,000,000 |
| Net Issuance Payments Of Debt | $8,051,000,000 | $8,901,000,000 | $8,650,000,000 | $-62,000,000 |
| Net Short Term Debt Issuance | $-4,338,000,000 | $-1,852,000,000 | $4,691,000,000 | $1,498,000,000 |
| Net Long Term Debt Issuance | $12,389,000,000 | $10,753,000,000 | $3,959,000,000 | $-1,560,000,000 |
| Long Term Debt Payments | $-778,000,000 | $-664,000,000 | $0 | $-1,560,000,000 |
| Long Term Debt Issuance | $13,167,000,000 | $11,417,000,000 | $3,959,000,000 | $0 |
| Net Investment Purchase And Sale | $319,000,000 | $-303,000,000 | $-223,000,000 | $-244,000,000 |
| Sale Of Investment | $964,000,000 | $374,000,000 | $508,000,000 | $463,600,000 |
| Purchase Of Investment | $-645,000,000 | $-677,000,000 | $-731,000,000 | $-707,600,000 |
| Net Business Purchase And Sale | $-661,000,000 | $-948,000,000 | $-1,044,000,000 | $-327,200,000 |
| Purchase Of Business | $-661,000,000 | $-948,000,000 | $-1,044,000,000 | $-327,200,000 |
| Net Intangibles Purchase And Sale | $-2,790,000,000 | $-2,745,000,000 | $-2,340,000,000 | $-1,035,200,000 |
| Sale Of Intangibles | $218,000,000 | $601,000,000 | $1,604,000,000 | $95,800,000 |
| Purchase Of Intangibles | $-3,008,000,000 | $-3,346,000,000 | $-3,944,000,000 | $-1,131,000,000 |
| Net PPE Purchase And Sale | $-7,841,000,000 | $-5,058,000,000 | $-3,448,000,000 | $-1,854,300,000 |
| Purchase Of PPE | $-7,841,000,000 | $-5,058,000,000 | $-3,448,000,000 | $-1,854,300,000 |
| Change In Working Capital | $-8,093,000,000 | $-5,384,000,000 | $-3,055,000,000 | $-800,000 |
| Change In Payables And Accrued Expense | $10,187,000,000 | $2,609,000,000 | $4,274,000,000 | $1,692,000,000 |
| Change In Payable | $10,187,000,000 | $2,609,000,000 | $4,274,000,000 | $1,692,000,000 |
| Change In Account Payable | $10,187,000,000 | $2,609,000,000 | $4,274,000,000 | $1,692,000,000 |
| Change In Prepaid Assets | $-6,609,000,000 | $-3,331,000,000 | $-3,453,000,000 | $-793,500,000 |
| Change In Inventory | $-4,671,000,000 | $-2,507,000,000 | $-1,425,000,000 | $-599,700,000 |
| Change In Receivables | $-7,000,000,000 | $-2,155,000,000 | $-2,451,000,000 | $-299,600,000 |
| Other Non Cash Items | $3,530,000,000 | $4,106,000,000 | $4,119,000,000 | $1,369,800,000 |
| Stock Based Compensation | $626,000,000 | $646,000,000 | $629,000,000 | $371,100,000 |
| Deferred Tax | $-1,707,000,000 | $-2,683,000,000 | $-2,341,000,000 | $-2,185,200,000 |
| Deferred Income Tax | $-1,707,000,000 | $-2,683,000,000 | $-2,341,000,000 | $-2,185,200,000 |
| Depreciation Amortization Depletion | $1,997,000,000 | $1,767,000,000 | $1,527,000,000 | $1,522,500,000 |
| Depreciation And Amortization | $1,997,000,000 | $1,767,000,000 | $1,527,000,000 | $1,522,500,000 |
| Gain Loss On Sale Of PPE | $-180,000,000 | $-224,000,000 | $-1,879,000,000 | $-156,500,000 |
| Net Income From Continuing Operations | $20,640,000,000 | $10,590,000,000 | $5,240,000,000 | $6,244,800,000 |
| Change In Other Current Assets | - | - | $-3,453,400,000 | $-793,500,000 |
| Change In Tax Payable | - | - | - | $346,600,000 |
| Change In Income Tax Payable | - | - | - | $346,600,000 |
| Sale Of Business | - | - | - | - |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-06-01